Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI105995

Studies on phenolic steroids in human subjects: VIII. Metabolism of estriol-16α-glucosiduronate

N. Inoue, A. A. Sandberg, J. B. Graham, and W. R. Slaunwhite Jr.

1Roswell Park Memorial Institute and The Medical Foundation of Buffalo, Buffalo, New York 14203

Find articles by Inoue, N. in: PubMed | Google Scholar

1Roswell Park Memorial Institute and The Medical Foundation of Buffalo, Buffalo, New York 14203

Find articles by Sandberg, A. in: PubMed | Google Scholar

1Roswell Park Memorial Institute and The Medical Foundation of Buffalo, Buffalo, New York 14203

Find articles by Graham, J. in: PubMed | Google Scholar

1Roswell Park Memorial Institute and The Medical Foundation of Buffalo, Buffalo, New York 14203

Find articles by Slaunwhite, W. in: PubMed | Google Scholar

Published February 1, 1969 - More info

Published in Volume 48, Issue 2 on February 1, 1969
J Clin Invest. 1969;48(2):380–389. https://doi.org/10.1172/JCI105995.
© 1969 The American Society for Clinical Investigation
Published February 1, 1969 - Version history
View PDF
Abstract

6,7-3H-Estriol-16α-glucosiduronate-14C was administered to eight women (nine studies) by several routes: both injection and infusion (300 min) into the cubital vein, injection into the portal vein system, ingestion and instillation into the duodenum, jejunum, and ileum. Urine, collected from 0-2, 2-4, 4-8, 8-12, and 12-24 hr, was analyzed by countercurrent distribution for its content of radioactive 3- and 16-glucosiduronate (E3-3Gl,E3-16Gl) and sulfoglucosiduronate (E3-3S,16Gl) of estriol as well as for 3H/14C ratio of each conjugate. After peripheral injection 50-60% of the injected E3-16Gl was excreted unchanged along with about 5% as E3-3S,16Gl with an unchanged 3H/14C ratio, indicating direct sulfation of the injected E3-16Gl. During a 300 min infusion, urinary excretion closely resembled that following injection. But 2-4 hr after the end of the infusion excretion of E3-3S, 16Gl stopped, excretion of E3-3Gl (17%/24 hr) with an elevated 3H/14C ratio started, and excretion of E3-16Gl continued (70%/24 hr), but with a rapidly increasing 3H/14C ratio. This indicated sequestration in a sluggishly metabolizing compartment where two processes occurred: (a) extensive hydrolysis of E3-16Gl followed by reconjugation at either C3 or C16 with unlabeled uridine diphosphate glucuronic acid (UDPGA), thereby increasing the 3H/14C ratio; and (b) transconjugation from C16 to C3, thereby producing E3-3Gl with finite 3H/14C ratios. Instillation into various segments of the small intestine produced results qualitatively similar to those after intravenous infusion, whereas ingestion and intraportal injection resembled peripheral intravenous injection. Therefore, we have postulated the possibility of an enteric circulation (in addition to an enterohepatic circulation) in which the steroid or its conjugates are transported into the small intestine in the succus entericus, modified, and then reabsorbed and excreted in the urine-a process which requires several hours.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 380
page 380
icon of scanned page 381
page 381
icon of scanned page 382
page 382
icon of scanned page 383
page 383
icon of scanned page 384
page 384
icon of scanned page 385
page 385
icon of scanned page 386
page 386
icon of scanned page 387
page 387
icon of scanned page 388
page 388
icon of scanned page 389
page 389
Version history
  • Version 1 (February 1, 1969): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts